Healthcare Industry News:  Noven Pharmaceuticals 

Biopharmaceuticals Personnel

 News Release - October 18, 2007

Nile Therapeutics Appoints Pedro Granadillo to Board of Directors

BERKELEY, Calif., Oct. 18 (HSMN NewsFeed) -- Nile Therapeutics, Inc. (OTC Bulletin Board: NILT.OB ), a biopharmaceutical company focused on developing therapies for cardiovascular disease, announced today that Mr. Pedro Granadillo was appointed on October 16, 2007 to serve on its board of directors. Mr. Granadillo is a highly-respected pharmaceutical industry leader with over 30 years of experience in corporate management, human resources, manufacturing and quality assurance.

"We are pleased to welcome such a widely respected and experienced senior pharmaceutical executive to our Board of Directors," said Peter Strumph, Chief Executive Officer of Nile. "Pedro brings to Nile more than three decades of industry knowledge and extensive pharmaceutical development and management experience. As we continue to drive our programs forward, it is imperative that we leverage the strategic guidance of leaders like Pedro who have a proven track record in drug development, corporate strategy and building effective teams and infrastructure."

Mr. Granadillo served as Senior Vice President for Eli Lilly and Company ("Lilly") until 2004 when he retired after 34 years of service. He was a member of Lilly's Policy Committee, which was comprised of its top seven executives. As Lilly's top human resources, manufacturing and quality executive, he was responsible for policies affecting a global workforce of more than 45,000 employees, as well as a broad network of manufacturing facilities for its extensive line of products. Mr. Granadillo led initiatives that brought Lilly wide recognition as a progressive employer. He also oversaw more than 20 sites and 13,000 employees involved in the manufacturing of Lilly's conventional "small-molecule" pharmaceuticals and "large-molecule" biotech therapies.

"I am honored to join Nile's board of directors," said Mr. Granadillo. "I look forward to working with the entire Nile management team as they move its pre-clinical and clinical pipeline forward and advance the company's strategic business objectives."

Mr. Granadillo is currently a member of the boards of directors of First Indiana Bank, Indianapolis, IN; Haemonetics Corporation of Braintree, MA; Noven Pharmaceuticals, Miami, FL; and Purdue University Research Foundation. Mr. Granadillo earned his B.S. degree in Industrial Engineering from Purdue University.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure, and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties. A key component of the Company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at www.nilethera.com.


Source: Nile Therapeutics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.